Dapagliflozin in heart failure and type 2 diabetes: Efficacy, cardiac and renal effects, safety

Figure 4 Comparison of changes in markers of myocardial infarction before and after treatment in two groups of patients. A: The changes of cardiac troponin I before and after treatment in two groups of patients; B: The changes of Creatine Kinase-MB before and after treatment in the two groups; C: The changes of N-Terminal pro b-type Natriuretic Peptide Precursor before and after treatment in the two groups. ^cP < 0.001. cTnI: Cardiac troponin I; CK-MB: Creatine Kinase-MB; NT-proBNP: N-Terminal pro b-type Natriuretic Peptide Precursor.